ENGN enGene Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1980845 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.6%
TTM EPS YoY305.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-60.5%
ROA-48.8%
ROIC (approx.)-60.4%
Asset turnover—
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio10.21x
Interest coverage-44.51x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $94.48M | $38.31M |
| SG&A expense | $28.68M | $23.98M |
| Operating income | -$123.17M | -$62.30M |
| Interest expense | $2.99M | $2.80M |
| Pretax income | -$117.30M | -$55.16M |
| Income tax | $0 | -$19,000 |
| Net income | -$117.30M | -$55.14M |
| EBITDA | -$122.67M | -$62.00M |
| EPS (basic) | 2.29 | 1.46 |
| EPS (diluted) | 2.29 | 1.46 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 51.12M | 37.78M |
| Balance sheet | ||
| Cash & equivalents | $50.15M | $173.00M |
| Short-term investments | $143.58M | $65.33M |
| Current assets | $201.39M | $247.36M |
| PP&E, net | $2.48M | $1.17M |
| Total assets | $221.47M | $311.17M |
| Current liabilities | $31.98M | $14.66M |
| Total liabilities | $53.76M | $38.56M |
| Shareholders' equity | $167.71M | $272.61M |
| Shares outstanding | 52.02M | 50.98M |
| Cash flow statement | ||
| Operating cash flow | -$99.24M | -$48.28M |
| Capital expenditure | $1.49M | $925,000 |
| Free cash flow | -$100.72M | -$49.21M |
| Investing cash flow | -$25.14M | -$125.95M |
| Financing cash flow | $1.52M | $265.72M |
| Depreciation & amortization | $500,000 | $300,000 |
| Stock-based compensation | $9.65M | $5.32M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.